Guatemala Regulatory Timeline 2023-2026: Standard Updates and the New Regulation
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Recent regulatory developments in Guatemala fall into two dense periods: the concentrated version changes of technical standards in 2023, and the wholesale replacement of the regulation in 2026. Within 2023 alone, more than eight technical standards took effect or were published; 2026 is marked by the G/TBT/N/GTM/106 notification, under which the new regulation is proposed to take effect on 2026-12-01 and repeal 712-99, which has been in force for 27 years. The two periods differ in character. The 2023 wave adjusted the technical standards layer, which determines the practical details of dossiers, premises and procedures. The 2026 change operates at the government agreement level, which is the foundation on which those standards rest. A regulatory monitoring ledger that captures both periods, keeps the dates straight, and is reviewed against the official sources on a fixed cycle is the working tool this article argues for. The chronology also serves as a bridge between the two periods: it places the 2026 dates alongside the 2023 wave so that a reader can see at a glance how the regulatory rhythm accelerated before the framework itself was put up for replacement.
2. Legal basis
The chronology below lists the regulatory events from 2022 to 2026, with the source relied on for each entry. The entries for 2023 are drawn from the current-texts section of the MSPAS website; the entries for 2026 are drawn from the WTO TBT notification. Dates shown in bold are the ones with direct scheduling consequences for in-flight projects.
| 2022-01-03 | RTCA 11.03.59:18 enters into force in Guatemala | Regional technical regulation |
| 2023-03-21 | NT 5, Versión 03-2023, “Manufacturing laboratories”, enters into force | MSPAS website, current-texts section |
| 2023-03-24 | NT 57, Versión 02-2023 (simplified procedure for switching from generic to brand names), enters into force | MSPAS website, current-texts section |
| 2023-04-19 | NT 90, Versión 01-2023, “Statutory period for applications for renewal of sanitary licences”, published | MSPAS website, current-texts section |
| 2023-06-15 | NT 92, Versión 1-2023 (repealing the GMP standard for sanitary products), enters into force | MSPAS website, current-texts section |
| 2023-06-27 | NT 77, Versión 08-2023, “Equivalence recognition for sanitary registration of medicines and vaccines”, enters into force | MSPAS website, current-texts section |
| 2023-07-20 | NT 67, Versión 6-2023, “Reference sanitary registration for biological and biotechnological products”, enters into force | MSPAS website, current-texts section |
| 2023-07-21 | NT 36, Versión 06-2023, “Market surveillance”, and NT 07, Versión 05-2023, “Wholesalers”, enter into force | MSPAS website, current-texts section |
| 2023-09-01 | NT 21, Versión 02-2023, “Pharmaceutical labelling”, enters into force | MSPAS website, current-texts section |
| 2023-10-01 | Resolución Número 01-2023 (repealing NT 83-2021 v2), enters into force | MSPAS website, current-texts section |
| 2026-02-11 | Notification to the WTO of G/TBT/N/GTM/106, the regulation for sanitary management and control of medicines and related products, 70 pages, in Spanish | WTO TBT notification |
| 2026-04-12 | Comment period for the new regulation closes (60 days from the notification) | WTO TBT notification |
| 2026-06-01 | Proposed adoption date of the new regulation | WTO TBT notification |
| 2026-12-01 | Proposed entry into force of the new regulation, with repeal of Acuerdo Gubernativo 712-99 | WTO TBT notification |
Base documents (current, for reference): Código de Salud, Decreto 90-97; Acuerdo Gubernativo 712-99 (1999-09-17); Acuerdo Gubernativo 115-99 (1999-02-24); NT 37 v5-2016 (2016-02-22); NT 40 v3-2015; NT 29 v2-2015 (updated 2015-10-08); NT 26-2016 v3-2017 (updated 2018-06-08); NT 27-2010; NT 19-2009; Apostille Convention in force for Guatemala since 2017-09-18.
3. Expert insights
Insight 1: The 2023 version changes concentrated in two directions. The first was premises and product standards (NT 5, NT 7, NT 21, NT 36, NT 67, NT 77); the second was procedural standards (NT 57, NT 90). In the same period there was also one repealing document (NT 92, Resolución 01-2023). This shows that 2023 was a systematic stock-take rather than scattered patching, and companies should read the wave as a single exercise in modernising the standards estate.
Insight 2: The 2026 change operates at a higher level. What changed in 2023 was the technical standards layer (the fourth level); what changes in 2026 is a government agreement (the third level). The higher the level, the wider the reach into downstream documents — 712-99 is the common empowering source of NT 37 and NT 40, so its repeal affects far more than any single NT version change could.
Insight 3: Two renewal-related standards deserve separate attention. NT 27-2010 (renewal of sanitary registrations) and NT 90 v01-2023 (statutory renewal periods) together constitute the time framework of the renewal procedure. Against the background of the 2026 replacement of the regulation, whether these two standards will be revised directly affects renewal scheduling, so they should be tracked individually in the monitoring ledger rather than folded into the general list.
Insight 4: The chronology itself needs continuous maintenance. Many Guatemalan technical standards use the formulation that they take effect from the date of publication on the directorate’s website (NT 37 Article 14), so the correspondence between publication date and effective date must be checked document by document. The chronology should be reviewed quarterly against the current-texts section of the MSPAS website, with new entries added and superseded entries annotated.
4. Practical recommendations
- Use this table as the skeleton of the regulatory monitoring ledger, review it quarterly and add new entries as they appear.
- Give particular attention to the 2026-12-01 milestone and decide the applicable rules for pipeline projects early.
- For renewal projects, check the period formulations of both NT 27-2010 and NT 90 v01-2023 together.
- Before citing any NT, verify the current version on the official website, avoiding reliance on repealed old versions.
- Maintain a cleanup list of repealed documents and remove them from the internal documentation system promptly.
5. Verification checklist
- □ Chronology maintained under a quarterly review mechanism
- □ 2026-12-01 milestone incorporated into project scheduling
- □ Renewal projects checked against NT 27-2010 and NT 90 v01-2023
- □ All cited NT standards verified against the current versions on the official website
- □ Cleanup list of repealed documents established
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Guatemalan market. Our team manages Ministry of Public Health and Social Assistance (MSPAS) registrations, coordinates import and distributor requirements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us